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Nicotinamide phosphoribosyltransferase (NAMPT) was originally reported as a pre–B-cell colony–enhancing 
factor, secreted by activated lymphocytes in bone marrow 
stroma.1 Intracellular NAMPT (iNAMPT) is the rate-limit-
ing enzyme in the salvage pathway of nicotinamide adenine 
dinucleotide (NAD+) generation.2 NAD+ acts as coenzyme in 
oxidative phosphorylation and as critical signaling regulator.3 
Accumulating evidence has highlighted the importance of 
NAMPT-mediated NAD+ recycling, in concert with NAD+-
dependent protein deacetylases (sirtuins), on the expression of 
peroxisome proliferator–activated receptors (PPARs), nuclear 
factor kappa B, and endothelial nitric oxide synthase,4,5 and 
indirectly on cellular proliferation, differentiation, stress 
responses, aging, and metabolism.6
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Objective—Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) mediates inflammatory and potentially 
proatherogenic effects, whereas the role of intracellular NAMPT (iNAMPT), the rate limiting enzyme in the salvage 
pathway of nicotinamide adenine dinucleotide (NAD)+ generation, in atherogenesis is largely unknown. Here we 
investigated the effects of iNAMPT overexpression in leukocytes on inflammation and atherosclerosis.
Approach and Results—Low-density lipoprotein receptor–deficient mice with hematopoietic overexpression of human 
iNAMPT (iNAMPThi), on a western type diet, showed attenuated plaque burden with features of lesion stabilization. This 
anti-atherogenic effect was caused by improved resistance of macrophages to apoptosis by attenuated chemokine (C–C 
motif) receptor 2-dependent monocyte chemotaxis and by skewing macrophage polarization toward an anti-inflammatory M2 
phenotype. The iNAMPThi phenotype was almost fully reversed by treatment with the NAMPT inhibitor FK866, indicating 
that iNAMPT catalytic activity is instrumental in the atheroprotection. Importantly, iNAMPT overexpression did not induce 
any increase in eNAMPT, and eNAMPT had no effect on chemokine (C–C motif) receptor 2 expression and promoted an 
inflammatory M1 phenotype in macrophages. The iNAMPT-mediated effects at least partly involved sirtuin 1–dependent 
molecular crosstalk of NAMPT and peroxisome proliferator–activated receptor γ. Finally, iNAMPT and peroxisome 
proliferator–activated receptor γ showed a strong correlation in human atherosclerotic, but not healthy arteries, hinting to a 
relevance of iNAMPT/peroxisome proliferator–activated receptor γ pathway also in human carotid atherosclerosis.
Conclusions—This study highlights the functional dichotomy of intracellular versus extracellular NAMPT, and unveils a 
critical role for the iNAMPT–peroxisome proliferator–activated receptor γ axis in atherosclerosis.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2017;37:1157-
1167. DOI: 10.1161/ATVBAHA.116.308187.)
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NAMPT also is released by cells to give rise to an extra-
cellular pool of NAMPT (eNAMPT), exerting cytokine-like 
activity.7 We have previously shown increased expression of 
NAMPT within atherosclerotic carotid plaques,8 and we and 
others have reported that eNAMPT promotes inflammatory 
and matrix degrading responses.7 Recently, hepatic NAMPT 
knockdown was seen to enhance atherosclerosis, at least partly 
mediated through eNAMPT,9 while concordant with this find-
ing, global systemic inhibition of NAMPT with FK866 damp-
ened plaque inflammation.10 However, the effects of iNAMPT 
on atherogenesis are only poorly understood.
Here, we examined the effects of specific upregulation of 
human iNAMPT in hematopoietic cells of low-density lipopro-
tein receptor–deficient (LDLr−/−) mice on plaque progression 
with special focus on myeloid cell function and phenotype.
Materials and Methods
Materials and Methods and Figure I are available in the online-only 
Data Supplement.
Results
Hematopoietic Human iNAMPT 
Overexpression Attenuates and Stabilizes 
Atherosclerotic Lesions in LDLr−/− Mice
In mice with hematopoietic lentiviral (LV)-iNAMPT overex-
pression (iNAMPThi chimeras), neither body weight (Figure IIA 
in the online-only Data Supplement), total plasma triglyceride 
(Figure IIB in the online-only Data Supplement), nor cholesterol 
(Figure IIC in the online-only Data Supplement) levels were 
influenced during 12 weeks on a western type diet. At euthniza-
tion, iNAMPT chimeras had similar plasma NAMPT levels as 
control mice (Figure 1A). However, bone marrow cells of the 
iNAMPThi chimera displayed upregulation of NAMPT mRNA 
and protein (65%, P<0.01; Figures 1B and 1C), an effect that was 
accompanied by a 2-fold increase in intracellular NAD+ levels 
(Figure 1D). A similar increase in iNAMPT expression was also 
seen 24 hours after LV infection (Figure IIE in the online-only 
Data Supplement). Apparently, LV gene transfer led to over-
expression of iNAMPT, but not eNAMPT, providing a unique 
opportunity to specifically study iNAMPT phenotypic effects.
Although early lesion development (6 weeks) in the aortic 
root tended to be reduced in iNAMPThi and control chimeras 
(Figure 2A), this effect was more pronounced and reached statis-
tical significance at 12 weeks on western type diet (Figure 2B). 
At 12 weeks, necrotic core size and plaque macrophage content 
(Figure 2C) were more than 50% decreased in the iNAMPThi 
chimera. The proportion of intimal apoptosis as assessed by acti-
vated caspase-3 staining was also reduced (Figure 2D). Plaques 
of iNAMPThi and control chimeras showed equivalent neutrophil 
(Figure IIIA in the online-only Data Supplement), T cell (Figure 
IIIB in the online-only Data Supplement), vascular smooth 
muscle cell (Figure IIIC in the online-only Data Supplement), 
and collagen content (Figure IIID in the online-only Data 
Supplement). To establish the involvement of NAMPT enzyme 
activity (and exclude off-target effects of the LV intervention) 
in the observed iNAMPT phenotype, we subjected a subgroup 
of iNAMPThi chimeras to NAMPT inhibitor treatment (FK866, 
10 mg/kg; twice a week) for 8 weeks. FK866 fully reversed 
the atheroprotective phenotype of iNAMPT mice, with plaque 
and necrotic core sizes not differing from those of LV-CTR 
(Figure IIIE in the online-only Data Supplement). Likewise, 
FK866 treatment increased plaque macrophage (Figure IIIF in 
the online-only Data Supplement) and caspase-3–positive cell 
(Figure IIIG in the online-only Data Supplement) contents of 
iNAMPThi mice that were similar to values in control mice. 
Unfortunately, however, we had no control with FK866 alone.
Thus, although we lack data on the whole aorta, we show 
significantly attenuated atherosclerosis in iNAMPThi at two 
time points: both at 6 and 12 weeks, and our FK866 inhibi-
tion experiments show a similar pattern for week 8. These data 
strongly indicate that the effect of atherosclerosis in these ani-
mals is not by chance.
Hematopoietic Human iNAMPT Overexpression 
Alters Myeloid Stromal Egress
We did not detect any changes in the number of circula-
tory CD3−B220+, CD3+CD4+, or CD3+CD8+ lymphocytes 
of splenic granulocytes or of monocytes in iNAMPThi ver-
sus control chimeras (data not shown). However, bone mar-
row of iNAMPThi chimeras was found to be enriched in 
CD11b+Ly6G+ granulocytes and CD11b+Ly6G− monocytes 
(Figure 3A). Although circulating granulocyte levels were 
not affected, monocyte counts were significantly reduced in 
iNAMPThi chimeras (Figure 3B). Analysis of bone marrow 
cells from iNAMPThi mice demonstrated the increased levels 
of total colony-forming units (CFU) compared with cells from 
the controls (Figure IVA in the online-only Data Supplement). 
This effect could be almost entirely ascribed to an increased 
frequency of CFU–GM (granulocyte-monocyte), CFU–G, 
and CFU–M (Figure IVB through D in the online-only Data 
Supplement), suggesting a myeloproliferative response to 
hematopoietic iNAMPT overexpression. However, circulating 
granulocytes were unchanged, whereas monocyte levels were 
reduced, suggestive of reduced stromal egress (monocytes) or 
increased stromal re-entry (granulocytes). Circulating, but not 
bone marrow granulocytes were reduced in CD62LloCXCR4hi 
cells, representing activated, senescent granulocytes prone to 
home to bone marrow (Figure 3C and 3D). This could reflect 
a diminished rate of neutrophil senescence or more effective 
stromal re-entry of senescent cells. Resident Ly6Clo mono-
cytes seemed to be overrepresented in bone marrow, result-
ing in lower Ly6Chi/Ly6Clo ratios (Figure 3C). This effect 
was paralleled to the predominance of Ly6Clo monocytes in 
circulation (Figure 3D). Consistent with an inhibitory role 
of iNAMPT in bone marrow Ly6Chi monocyte mobilization, 
FK866 treated LDLr−/− mice exhibited reduced stromal bone 
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marrow monocyte content (Figure IVE in the online-only Data 
Supplement) and increased number of circulating monocytes 
(Figure IVF in the online-only Data Supplement).
One of the key regulatory pathways in stromal monocyte 
egress is the chemokine (C–C motif) receptor 2 (CCR2)–C-C 
chemokine ligand 2 (CCL2) axis.11 Gene and protein analysis of 
CCR2 in bone marrow–derived macrophages (BMDMs) from 
iNAMPThi versus control chimera revealed a strong downregu-
lation (Figure 4A and 4B and Figure VA in the online-only Data 
Supplement). Moreover, although CCL2 mRNA expression 
remained unchanged (Figure 4C), CCL2 secretion was slightly 
decreased in iNAMPThi chimeras (Figure 4D). Remarkably, 
incubation of BMDMs from iNAMPThi or control chimeras 
with eNAMPT did neither affect CCR2 and CCL2 mRNA 
levels nor CCL2 secretion (Figures 4B and 4C). As baseline 
and fMLP (N-formylmethionyl-leucyl-phenylalanine) elicited 
cell motility (Figure 4E) and directional migration (Figure 
4F) were both sharply diminished in BMDMs of iNAMPThi 
versus control chimeras, it is conceivable that iNAMPT over-
expression compromises the general migratory capacity of 
monocytes. An inverse pattern was seen for BMDMs isolated 
from FK866 treated mice, which had augmented motility; 
while again eNAMPT treatment was ineffective (Figure 4F). 
Importantly, overexpressed iNAMPT was not secreted (ie, no 
increase in eNAMPT; Figure 4G). Moreover iNAMPThi, but 
not eNAMPT, caused increases in intracellular, but not extra-
cellular NAD+ levels (Figure 4H). Our data again confirm that 
iNAMPT’s activity in our model is strictly confined to the intra-
cellular compartment. Recently, Li et al9 show that manipulat-
ing NAMPT expression within the liver influenced eNAMPT 
levels, and indeed, when examining NAMPT secretion after 
LV-NAMPT overexpression in parenchymal liver cells (HepG2 
cells) in vitro we found that in contrast to BMDM, hepatocyte 
NAMPT is elaborated into medium (Figure VB in the online-
only Data Supplement) suggesting that the release of eNAMPT 
at least partly is regulated in cell-specific manner.
Hematopoietic Human iNAMPT 
Overexpression Favors Alternatively 
Activated Macrophage Polarization
In inflammation, Ly6Chi monocytes are recruited to the 
affected tissue via CCR2, among others, to give rise to clas-
sically activated M1 macrophages.12 In iNAMPThi chimeras, 
Ly6Clo monocytes were however found to be the predominant 
subset. We therefore hypothesized that iNAMPT overexpres-
sion is accompanied by skewing of macrophage differentiation 
toward alternatively activated M2 macrophages, known for 












































































































Figure 1. Hematopoietic intracellular nicotinamide phosphoribosyltransferase (iNAMPT) overexpression does not affect extracellular 
NAMPT (eNAMPT) plasma levels but results in an increased expression and function of iNAMPT in bone marrow–derived macrophages 
(BMDMs) from LDLr−/− mice. Animals were fed a high-fat western type diet for 12 weeks (n=12). A, Plasma levels of eNAMPT. B, iNAMPT 
gene expression in spleen. iNAMPT gene (C) and protein (D) expression in BMDMs. E, Intracellular NAD+ levels in BMDMs. *P<0.05, 
**P<0.01, ***P<0.001 vs CTR chimera. CTR indicates control.
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Figure 2. Hematopoietic intracellular nicotinamide phosphoribosyltransferase (iNAMPT) overexpression attenuates atherosclerotic plaque 
development in LDLR−/− mice. A and B, Hematoxylin–eosin staining of aortic roots with corresponding quantification of plaque size after 
a high-fat western type diet for 6 (A) or 12 (B) weeks. C and D, Immunostaining for MAC3 (C) and caspase-3 (D) of aortic roots with cor-
responding quantification, including necrotic core area relative to intima surface (C) after a high-fat western type diet for 12 weeks (n=12). 
*P<0.05, **P<0.01, ***P<0.001 vs CTR chimera. CTR indicates control.
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Figure 3. Hematopoietic intracellular nicotinamide phosphoribosyltransferase (iNAMPT) overexpression perturbs stromal and circulating 
leukocyte pools in LDLR−/− mice. Animals were fed a high-fat western type diet for 12 weeks (n=12). Fluorescence-activated cell sorting 
(FACS) analysis of absolute granulocyte (CD11b+Ly6G+) and monocyte (CD11b+Ly6G−) counts in bone marrow (A and B) and blood (C and 
D). Proportions of (E and F) activated, senescent granulocytes (CD62LloCXCR4hi) and of (G and H) Ly6Chi–to–Ly6Clo subsets in bone mar-
row (BM; G) and blood (H). Gating strategies are demonstrated in the lower panels *P<0.05 vs CTR chimera. CTR indicates control.
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In agreement with this hypothesis, iNAMPThi BMDMs, polar-
ized with interferon-γ and lipopolysaccharide (M1) or inter-
leukin-4 (IL-4) (M2), showed reduced or increased expression, 
respectively, of established M1 (tumor necrosis factor, IL-6 
and inducible nitric oxide synthase) and M2 (IL-10, arginase 
1 and to a lesser extent mannose receptor, C-type 1) markers 
relative to control BMDMs (Figure VIA in the online-only 
Data Supplement). In contrast, exposure of BMDMs from 
control mice to eNAMPT led to upregulated tumor necrosis 
factor and IL-6 expression at mRNA level and protein secre-
tion. eNAMPT was also able to induce these inflammatory 
cytokines in iNAMPThi BMDMs, albeit less pronounced than 
in control BMDMs (Figure VIB and C in the online-only Data 
Supplement). It is worth noting that hematopoietic iNAMPT 
overexpression did not confer systemic anti-inflammatory 
effects, as judged by the unaltered plasma cytokine patterns 
observed in iNAMPThi compared with control chimeras 






Figure 4. Hematopoietic intracellular nicotinamide phosphoribosyltransferase (iNAMPT) overexpression impairs the migratory response 
in bone marrow–derived macrophages (BMDMs) from LDLR−/− mice. Animals were fed a high-fat western type diet for 12 weeks (n=12). 
Gene (A) and protein (B) expression of chemokine (C–C motif) receptor 2 (CCR2) with corresponding quantification in BMDMs. Gene 
expression (C) and secretion (D) of C-C chemokine ligand 2 (CCL2) in BMDMs. E, Percentages of migrating cells at 0, 12 and 24 hours 
after wound healing of BMDMs. F, Cells migrating in response to each condition divided by cells migrating in response to medium alone. 
Levels of eNAMPT (G) and NAD+ (H) in the medium of BMDMs. Cells were treated with FK866 (500 nmol/L), recombinant eNAMPT (100 
ng/mL), or fMLP (N-formylmethionyl-leucyl-phenylalanine; 1 nmol/L) as indicated for 24 hours, except where otherwise specified. *P<0.05, 
**P<0.01 vs CTR chimera vs untreated cells. CTR indicates control.






Figure 5. PPARγ is a downstream effector of intracellular nicotinamide phosphoribosyltransferase (iNAMPT) via sirtuin 1 (SIRT1) in bone 
marrow–derived macrophages (BMDMs) from LDLR−/− mice. Animals were fed a high-fat western type diet for 12 weeks (n=12). Gene (A) 
and protein (B) expression of PPAR and SIRT1 with corresponding quantification in BMDMs. Gene expression of M1 markers (C), che-
mokine (C–C motif) receptor 2 (CCR2) and C-C chemokine ligand 2 (CCL2; D), and migration index (E) in BMDMs from indicated mice 
models. Cells were treated with EX-527 (SIRT1 inhibitor, 1 M) or fMLP (N-formylmethionyl-leucyl-phenylalanine; 1 nmol/L) as indicated for 
24 hours. *P<0.05, **P<0.01 vs CTR chimera vs iNAMPThi chimera. iNOS indicates inducible nitric oxide synthase; IL, interleukin; and TNF, 
tumor necrosis factor. CTR indicates control.
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Hematopoietic Human iNAMPT 
Overexpression Promotes PPARγ Activation 
in an SIRT1-Dependent Manner
PPARγ has been proposed as a key regulator of M2 polariza-
tion.14 Interestingly, in silico pathway analysis (string-db.org) 
linked PPARγ to NAMPT (Figure VII in the online-only Data 
Supplement), pointing to a potential involvement of PPARγ 
in iNAMPThi associated M2 polarization. In search of the 
molecular pathway of iNAMPT’s anti-inflammatory activity, 
we assessed whether iNAMPT is able to interact directly with 
PPARγ or via its immediate effector enzyme, sirtuin 1 (SIRT1), 
which is reported to regulate PPARγ activity.13 BMDMs from 
iNAMPThi chimeras featured upregulated expression of PPARγ 
and its regulator SIRT1 when compared with control (Figures 
5A and 5B). However, conditional deletion of PPARγ (ie, 
LysM–Cre/PPARγflox/flox), even if iNAMPT was overexpressed, 
or SIRT1 inhibition had no effects on iNAMPT expression or 
NAD+ levels in BMDMs (data not shown). We further stud-
ied the effect of iNAMPThi on polarization of wild-type ver-
sus PPARγ-deficient macrophages. LysM-Cre/PPARγflox/flox 
BMDMs infected with control and iNAMPT LV were used to 
determine whether the polarizing effects of iNAMPT overex-
pression were mediated via PPARγ. As expected, macrophage 
deficiency in PPARγ led to a profound increase in M1 marker 
expression (Figure 5C). Unlike in control BMDMs, however, 
iNAMPThi overexpression was unable to alter M1 marker gene 
expression in LysM-Cre/PPARγflox/flox BMDMs. Similar find-
ings were obtained after inhibiting SIRT1 (Figure 5C). CCR2 
and CCL2 were upregulated in PPARγ deficient cells, indicat-
ing a regulatory link between PPARγ and the CCR2 axis (Figure 
5D). Hematopoietic iNAMPT overexpression failed to suppress 
CCR2 expression in LysM-Cre/PPARgflox/flox BMDMs, whereas 
it reverted CCL2 expression to levels observed in control and 
iNAMPThi BMDMs from wild-type mice (Figure 5D). In keep-
ing with the lack of effect on CCR2, iNAMPThi did not have any 
effects on LysM-Cre/PPARγflox/flox BMDMs migratory capacity 
(Figure 5E). Unlike iNAMPT, eNAMPT did not impact on 
PPARγ or SIRT1 expression (data not shown), once again con-
firming the divergent activity profile of iNAMPT and eNAMPT. 
Collectively, these data reveal the SIRT1–PPARγ axis as a 
downstream effector pathway in the iNAMPThi-induced macro-
phage reprogramming toward an M2 phenotype.
Hematopoietic Human iNAMPT Overexpression 
Modulates Lipid Homeostasis
The tight interplay between iNAMPT and PPARγ, a master 
regulator of lipid handling in macrophages15 and the iNAMPT-
associated increase in intracellular levels of NAD+, which 
may affect lipid metabolism as well,16 hinted toward an effect 
of iNAMPT overexpression on macrophage lipid handling. 
In line with the aforementioned iNAMPT-induced upregula-
tion of PPARγ in BMDMs, LysMCre-PPARγflox/flox BMDMs 
showed intrinsically reduced PPARγ mRNA expression, which 
was not affected by iNAMPT overexpression, but iNAMPT 
augmented oxidized low-density lipoprotein-induced PPARγ 
upregulation in BMDMs (Figure VIIIA in the online-only Data 
Supplement). ABCA1 (ATP-binding cassette transporter 1) 
and ABCG1 (ATP-binding cassette sub-family G member 1) 
expression patterns essentially mirrored that of PPARγ (Figure 
VIIIB through D in the online-only Data Supplement). In con-
trast to its profound effect in BMDMs, iNAMPT had no effect 
on ABCA1 and ABCG1 and LXRα (liver X receptor alpha) 
expression in the liver, again underpinning the leukocyte-spe-
cific nature of the intervention (Figure VIIID through F in the 
online-only Data Supplement). As a result, cholesterol ester 
accumulation at baseline and in oxidized low-density lipopro-
tein-exposed BMDMs of iNAMPThi chimera was attenuated, 
when compared with that in control chimera (Figure VIIIG in 
the online-only Data Supplement). Our findings, thus, suggest 
that iNAMPT is involved in the PPARγ-dependent modulation 
of macrophage lipid homeostasis.
NAMPT and PPARγ Expression Are Tightly 
Correlated in Human Atherosclerosis
Finally, we set out to verify whether the disclosed mutual inter-
action between NAMPT and PPARγ is also relevant in the 
context of human atherosclerosis. As an extension of a previ-
ous study showing increased expression of NAMPT in carotid 
lesions of patients with symptomatic disease (ie, stroke or 
TIA),8 we found that these patients also exhibited a profound 
upregulation of NAMPT gene expression in peripheral blood 
mononuclear cells (Figure 6A). PPARγ and NAMPT expres-
sion levels were also assessed in atherosclerotic and iliac artery 
specimens (Oslo cohort) and in specimens from a carotid artery 
cohort containing early, advanced, and ruptured carotid plaques 
(the Maastricht Human Plaque study). Relative NAMPT mRNA 
(RT-PCR; Figure 6B) and protein expression (immunohisto-
chemistry; Figure 6C) both increased progressively from early 
stable lesions to advanced and ruptured plaques (the Maastricht 
Human Plaque study). Plaque NAMPT (red) colocalized with 
the macrophage marker CD68 (green) and virtually no NAMPT 
staining was observed in CD68-negative cells, but not all 
CD68-positive cells were positive for NAMPT. This colocaliza-
tion could be confirmed by confocal microscopical assessment 
(Oslo cohort, Figure 6D). Moreover, we observed a significant 
correlation between NAMPT and PPARγ expression in ath-
erosclerotic (Figure 6E), but not healthy (Figure 6F) arteries; 
at which NAMPT and PPARγ expression correlation changes 
with progressive atherosclerotic disease (Figure 6G). Finally, 
as NAMPT was mainly expressed by plaque macrophages, the 
increased NAMPT expression in advanced lesions could mirror 
an enhanced inflammatory nature of ruptured plaques, rather 
than an intrinsic upregulation in plaque macrophages. In sup-
port of this hypothesis, we found that NAMPT and CD68 were 
strongly correlated within carotid artery plaques (Figure 6H).
Discussion
eNAMPT and iNAMPT have been suggested to exert diver-
gent functions. In humans, circulating eNAMPT has already 
been associated with atherosclerosis, both in experimental 
and epidemiological studies.17 The causal involvement of 
iNAMPT in this disease is, however, still unclear. This study 
is the first to address the role of leukocyte iNAMPT in athero-
genesis. Using gain/loss-of-function approaches in vitro and 
in vivo, we show that the activity spectrum of iNAMPT dif-
fers profoundly from that of eNAMPT, and that LV iNAMPT 
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gene transfer does not change eNAMPT or extracellular NAD+ 
levels. We demonstrate that hematopoietic iNAMPT overex-
pression confers protection against atherosclerosis by affect-
ing on 3 hallmark processes: (1) improving the resistance of 
macrophages to apoptosis, (2) attenuating monocyte intravasa-
tion and migration in response to chemotactic signals, and (3) 
skewing monocyte differentiation and macrophage polariza-
tion toward an anti-inflammatory M2 phenotype. The iNAMP-
Thi phenotype was almost completely reversed by treatment 
with the enzyme inhibitor FK866, indicating that iNAMPT 
catalytic activity is instrumental in the atheroprotection.
Interestingly, Li et al9 have recently shown that increased 
hepatic NAMPT expression promotes atherosclerosis, which 
may seem in conflict with the present study. However, this 
study differs in several aspects from our study. In Li et al’s9 
study adenoviral overexpression of NAMPT resulted in 
increased expression by liver parenchymal cells, which are 
critical in glucose and lipid metabolism, whereas we have 
investigated NAMPT overexpression in leukocytes. Indeed, 
enhanced hepatic NAMPT expression will have pronounced 
effects on glucose metabolism18 and tolerance, on plasma lipo-
protein levels, and on lipogenic key genes (increased PPARα, 
LXRα, ABCA1, and ABCG1 expressions). In our model, 
none of these effects were observed, underpinning the leuko-
cyte specificity of our approach.
Another major discrepancy is related to the differential 
functions of iNAMPT versus eNAMPT. Adenoviral gene trans-
fer markedly elevated NAMPT levels in plasma (eNAMPT),9 
whereas our approach only affected iNAMPT expression as 
judged from (1) unchanged eNAMPT plasma levels in vivo in 
iNAMPThi chimeras and (2) unchanged eNAMPT secretion by 
iNAMPThi BMDM in vitro. Importantly, we and others have 
Figure 6.  Nicotinamide phosphoribosyltransferase (NAMPT) and PPARγ are players in human atherosclerosis. A, Gene expression of 
NAMPT in human peripheral blood mononuclear cells (PBMCs; n=59, 18 for healthy). Gene expression (B; n=13, 6 for IPH) and immuno-
histochemistry with corresponding quantification (C; n=3) of NAMPT in human carotid plaques at early (PIT), advanced stable (TkFCA), 
and unstable (IPH) stages. D, Colocalization of NAMPT with CD68. Spearman correlations between NAMPT and PPARγ in human carotid 
plaques (E; n=59), iliac normal arteries (F; n=18), and carotid plaques at different stages of atherosclerosis (G; n=41). H, Pearson correla-
tion between 2log NAMPT intensity and relative CD68 intensity/tissue area. **P<0.01 vs control PBMCs. *P<0.05, **P<0.01, ***P<0.001 vs 
PIT plaques vs TkFCA plaques.
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previously reported that although eNAMPT exerts inflamma-
tory and potentially proatherogenic activities,7 the effects of 
iNAMPT may, in fact, be opposite. For instance, we show that 
iNAMPT downregulate CCR2 expression and suppress mono-
cyte chemotaxis, whereas exposure of cells to eNAMPT was 
completely ineffective. The functional dichotomy of iNAMPT 
versus eNAMPT is partly related to the differences in extracel-
lular and intracellular NAD+ produced by NAMPT. Intracellular 
NAD+ will activate sirtuin proteins, which through histone 
deacetylation lead to, for example, modulation of gene tran-
scription.2 Extracellular NAD+, however, can bind and activate 
extracellular receptors, such as P2X7R triggering inflammatory 
pathways (eg, NLRP3 inflammasome activation).19 Importantly, 
we show that leukocyte iNAMPT overexpression promotes 
increased intracellular, but not extracellular, NAD+ levels, and 
ensuing activation of SIRT1 pathways. Again no such effects 
were seen when exposing cells to eNAMPT. The contrasting 
results of our current study and the inverse, anti-inflammatory 
phenotype of systemic or cellular NAMPT inhibition by FK866, 
reported by Nencioni et al10 and Halvorsen et al,20 may also 
be viewed from this perspective, in that they reflect different 
functions of intracellular and extracellular NAMPT. Although 
FK866 inhibits both intracellular and extracellular NAMPT, 
Yano et al21 have recently shown that FK866 also inhibit the 
release of extracellular NAMPT from monocytes, potentially 
leading to eNAMPT skewed inhibition. In our present study, 
however, there was a selective upregulation of iNAMPT, and 
accordingly, the effect of FK688 in this setting will only reflect 
iNAMPT inhibition. Finally, we cannot exclude that effects of 
NAMPT inhibition (FK86610,20 and siRNA9) are not completely 
reciprocal to that of NAMPT overexpression (this study).
Taken together, the seemingly paradoxical results of our 
study compared with that of previous work on systemic or 
hepatic inhibition can be attributed to the diverging activities 
of intracellular and extracellular NAMPT, as well as the diverg-
ing roles of NAMPT in hepatocytes versus leukocytes. It could 
also reflect that regulation of eNAMPT at least partly is cell 
specific. In contrast to our understanding of iNAMPT, the regu-
lation of eNAMPT is poorly understood.22 Possibly, the release 
of eNAMPT is regulated at post-transcriptional or even post-
translational level, in a cell-specific manner. Indeed, herein we 
show after LV-NAMPT overexpression in parenchymal liver 
cells (HepG2 cells) in vitro hepatocyte NAMPT is elaborated 
into medium. Our approach, thus, provides insights into the 
anti-inflammatory activity of leukocyte iNAMPT expression 
and the different regulation eNAMPT and iNAMPT and in that 
sense our study adds to a better understanding and specification 
of NAMPTs complex functions in atherosclerosis (Graphical 
Abstract in the online-only Data Supplement).
Another striking finding in this study was that plaques of 
iNAMPThi chimeras displayed reduced macrophage accumu-
lation. We propose 2 major pathways for this phenomenon. 
First, iNAMPT overexpression in hematopoietic cells was 
associated with a reduced abundance of Ly6Chi monocytes 
in circulation, which are less prone to home to atheroscle-
rotic plaque.12 The reduction was not because of diminished 
stromal Ly6Chi production, as we even observed augmented 
myelocyte CFU levels in bone marrow of iNAMPThi chime-
ras, pointing to increased myeloproliferation. As circulating 
monocyte numbers, in particular of the Ly6Chi subset, were 
lowered in iNAMPThi mice, this could reflect compromised 
Ly6Chi monocyte egress the traffic and their recruitment 
to plaque. In fact, we demonstrate reduced CCR2 expres-
sion and CCL2 chemotaxis in iNAMPThi macrophages, a 
proper function of which is critical for monocyte intravasa-
tion.12,23 We were able to attribute these chemotactic effects 
to iNAMPT-dependent activation of the PPARγ pathway. The 
latter is known to downregulate CCR2 expression,24 and our 
findings suggest that downregulation of CCR2 expression is 
linked to SIRT1-dependent PPARγ activation. Indeed, both 
SIRT1 and PPARγ inhibition counteracted the lowered CCR2 
expression and activity in iNAMPThi BMDM. The potential 
molecular crosstalk of NAMPT and PPARγ and the capac-
ity of iNAMPT-derived NAD+ to activate SIRT1,25 all concur 
with an involvement of the iNAMPT/NAD+ salvage pathway 
on SIRT1-dependent PPARγ activity, and seems to be of 
major importance in mediating the atheroprotective effects of 
iNAMPT in our model (see Graphical Abstract).
One could argue that our BM transduction protocol will 
target not only hematopoietic precursor cells but also other 
cell types, such as endothelial and mesenchymal progenitor 
cells. First, we show the significant upregulation of iNAMPT 
in BMDM from iNAMPThi chimera and in the spleen being a 
reliable reflection of leukocyte overexpression in these mice. 
Moreover, even if endothelial and mesenchymal progenitor 
cells are (over) expressed iNAMPThi, they will only represent a 
minute fraction of circulating NAMPT+ cells (≈0.001% or 102 
endothelial progenitor cells/mL). Even more importantly, endo-
thelial and mesenchymal progenitor cells have been repeatedly 
shown to not contribute to EC or smooth muscle cell renewal in 
the atherosclerotic plaque,26,27 and it is, therefore, unlikely that 
NAMPT expression in nonhematopoietic cells would have con-
tributed significantly to the observed phenotype in our study.
In conclusion, this study is the first to demonstrate a pro-
tective role for leukocyte iNAMPT in western diet–induced 
atherosclerosis in LDLr−/− mice, with reduced macrophage 
accumulation and augmented lesion stability as most prominent 
features. iNAMPT was shown to compromise extravasation and 
mobilization of monocytes out of the bone marrow, via its down-
stream effector PPARγ, leading to reduced accumulation of 
macrophages in plaque. Moreover, it led to reduced macrophage 
apoptosis, possibly in a PPARγ/SIRT1-dependent fashion, and 
induced an anti-inflammatory gene program in macrophages 
(see Graphical Abstract). Finally our study suggests that the 
increased NAMPT expression in human atherosclerotic plaques 
could involve a counteracting and beneficial response. Further 
data (eg, prognostic data on NAMPT expression within human 
carotid plaques), are, however, needed to prove this hypothesis. 
Our data also point toward caution when attempting to target 
NAMPT in relevant disorders such as atherosclerosis. We suggest 
that therapeutic approach should preferably inhibit eNAMPT 
without inhibiting or even increase iNAMPT, but these issues 
will have to be further clarified in forthcoming studies.
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Highlights
• Hematopoietic intracellular nicotinamide phosphoribosyltransferase (iNAMPT) overexpression attenuates and stabilizes diet–induced athero-
sclerosis.
• iNAMPT mediates sequestration of proinflammatory monocytes in bone marrow.
• Macrophages are skewed toward alternative polarization by iNAMPT via PPARγ.
• iNAMPT overexpression did not induce extracellular NAMPT (eNAMPT), and eNAMPT had no effect on chemokine (C–C motif) receptor 2 expres-
sion and promoted an inflammatory M1 phenotype in macrophages.
• Gene NAMPT and PPARγ expression tightly correlate with progression of atherosclerotic lesions in humans.
